On January 31, 2023 FibroBiologics, a clinical-stage company focused on the development of
fibroblast cell-based therapeutics for chronic diseases, reported an online funding campaign with StartEngine, a leading equity crowdfunding platform (Press release, FibroBiologics, JAN 31, 2023, View Source [SID1234627693]). Regulation Crowdfunding allows everyone to invest in securities issued by startup companies, regardless of their net worth or income level.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The funding will be used to support the Company’s ongoing operations and advance clinical programs in multiple sclerosis, degenerative disc disease, wound care, extension of life, and cancer.

"We’re excited to partner with StartEngine on this campaign. StartEngine has over 600,000 investors as part of their community and has raised over half a billion dollars for its clients," said FibroBiologics’ Founder and CEO, Pete O’Heeron. "This is an exciting time at FibroBiologics as we continue progressing our clinical pipeline and developing innovative therapies to treat chronic diseases. This new funding will fuel our growth in the lab and bring us one step closer to commercialization."

For more information, please visit FibroBiologics’ website or email FibroBiologics at [email protected]. To invest in FibroBiologics, please go to the company’s campaign on StartEngine startengine.com/fibrobiologics.